PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8233279

Does Doppler-detected fetal movement decrease the incidence of nonreactive nonstress tests?

L M Stanco·Y Rabello·A L Medearis·R H Paul
View original source ↗Export metadata ↓

Abstract

OBJECTIVE: To determine whether a decreased incidence of nonreactive nonstress tests (NSTs) in antepartum testing was attributable to the addition of fetal movement detection to the standard NST. METHODS: Monitors with standard fetal heart rate recording capabilities were used, as were new monitors producing a Doppler-detected recording of fetal movement (NST-fetal movement). Cross-sectional retrospective analysis of NST results was carried out by chi 2. RESULTS: Comparison of the 10-month period before fetal movement detection to the 10 months including NST-fetal movement monitoring showed a significant decrease in nonreactive NSTs from 5.7% to 3.3% (chi 2 = 61.7, 95% confidence interval [CI] 0.97-0.98). This reduction in nonreactive tests disappeared (3.3% to 5.1%) when the NST-fetal movement-capable monitors were no longer available (chi 2 = 24.2, 95% CI 1.01-1.03). CONCLUSIONS: Nonreactive NSTs decreased by 58% with the introduction of fetal movement monitoring in our antepartum testing center and increased when the NST-fetal movement-capable monitors were removed. A reduced incidence of nonreactive NSTs associated with NST-Doppler-detected fetal movements should effect a savings in both time and resources.

Explore related subjects

Chi-Square DistributionCross-Sectional StudiesFemaleFetal MonitoringFetal MovementHeart Rate, FetalHumansPregnancyRetrospective StudiesUltrasonography, PrenatalJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L M Stanco, Y Rabello, A L Medearis, R H Paul. 1993. Does Doppler-detected fetal movement decrease the incidence of nonreactive nonstress tests?. https://pubmed.ncbi.nlm.nih.gov/8233279/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.

OBJECTIVE: To evaluate the efficacy of pentoxifylline therapy in improving the walking capacity of patients with moderate intermittent claudication. DATA SOURCES: A search of MEDLINE for trials published between 1976 and 1994 inclusive, and a bibliographic review of all articles retrieved. STUDY SELECTION: Randomized, placebo-controlled, double-blind clinical trials were selected that evaluated the pain-free walking distance (the distanced walked on a treadmill before the onset of calf pain) and the absolute claudication distance (the maximum distance walked on a treadmill) among patients with moderate intermittent claudication. Twelve study groups in 11 trials were included in the analysis. DATA EXTRACTION: In addition to information regarding the trial design, patient characteristics, dosages and treatment periods, the means and standard deviations were collected for both the pain-free walking and absolute claudication distances. Trial quality was also assessed. DATA SYNTHESIS: Overall, there was a statistically significant improvement in the pain-free walking distance after pentoxifylline therapy (weighted mean difference 29.4 m [95% confidence interval (CI) 13.0 to 45.9 m]); this finding was based on a total sample of 612 patients (308 in the treatment groups and 304 in the control groups). A significant improvement was also noted in the absolute claudication distance (weighted mean difference 48.4 m [95% CI 18.3 to 78.6 m]); this was based on a total sample of 511 patients (258 in the treatment group and 253 in the control group). In a sensitivity analysis of the pain-free walking distance, significant treatment effects and no statistically significant heterogeneity were found when only trials were included that were "medically eligible" (involved patients with stage II disease and a pain-free walking distance of 50 to 200 m). In a similar sensitivity analysis of the absolute claudication distance, the two conditions resulting in a significant treatment effect and no significant heterogeneity were the inclusion of "medically eligible" trials and those with a shorter treatment duration (13 weeks or less). CONCLUSION: Pentoxifylline therapy may be efficacious in improving the walking capacity of patients with moderate intermittent claudication. However, properly conducted clinical trials are required to provide a true estimate of the benefit.

Chi-Square Distribution↗
PubMed1996

Interlaboratory variability in fluorescence in situ hybridization analysis. The NCI Bladder Tumor Marker Network.

Reliable interpretation of fluorescence in situ hybridization (FISH) data, especially data that have been generated in more than one laboratory, requires knowledge of the sources of variability inherent in FISH analysis. Possible sources of variation may derive from differences in sample preparation, probes used, intrasample heterogeneity, hybridization protocols, counting criteria within and between scorers, fluorescence microscopes, and filters. This study characterized the relative weight of some of these factors in order to determine the degree to which FISH results are comparable between laboratories. We used a hierarchical partitioned chi 2 analysis to measure sources of variation. We found that replicate counts varied no more than expected based on counting statistics (i.e., multinomial variation). However, with replicate hybridizations done in two separate laboratories, the variability increased significantly. Thus, care must be taken when interpreting FISH data that are derived from more than one institution. Previously agreed upon counting criteria as well as standardized FISH hybridization protocols may decrease this variability.

Chi-Square Distribution↗
PubMed1996

Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders.

Several studies have reported an association between schizophrenia and homozygosity for the MscI restriction site in exon 1 of the D3 dopamine receptor gene, but other studies have failed to find this association. Recent reports have suggested that the association is most salient in male patients with a family history of schizophrenia. We examined this restriction site in a group of schizophrenic patients (n = 84) and in normal controls (n = 77). Patients were subdivided according to demographic and clinical features, particular attention being paid to movement disorders. No significant difference in allelic or genotypic distribution was seen between the two groups. No association was seen between homozygosity and a positive family history, age at onset of illness, clinical subtype, negative symptom score, or movement disorder scores.

Chi-Square Distribution↗